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Abstract
Aberrant DNA methylation is important in multiple myeloma pathogenesis. Methylation of p15, p16, p53, and
DAPK genes was evaluated in bone marrow (94 patients; 8 controls) by methylation-speciﬁc polymerase chain
reaction; 63% of patients with multiple myeloma and 39% of patients with monoclonal gammopathy of un-
certain signiﬁcance presented ‡1 hypermethylated gene (P < .05). This supports a relevant role for hyper-
methylation in the pathogenesis of the plasma cell neoplasms.
Background: Aberrant DNA methylation is considered a crucial mechanism in the pathogenesis of monoclonal
gammopathies. We aimed to investigate the contribution of hypermethylation of 4 tumor suppressor genes to the
multistep process of myelomagenesis. Methods: The methylation status of p15, p16, p53, and DAPK genes was
evaluated in bone marrow samples from 94 patients at diagnosis: monoclonal gammopathy of uncertain signiﬁcance
(MGUS) (n ¼ 48), smoldering multiple myeloma (SMM) (n ¼ 8) and symptomatic multiple myeloma (MM) (n ¼ 38), and
from 8 healthy controls by methylation-speciﬁc polymerase chain reaction analysis. Results: Overall, 63% of patients
with MM and 39% of patients with MGUS presented at least 1 hypermethylated gene (P < .05). No aberrant
methylation was detected in normal bone marrow. The frequency of methylation for individual genes in patients with
MGUS, SMM, and MM was p15, 15%, 50%, 21%; p16, 15%, 13%, 32%; p53, 2%, 12,5%, 5%, and DAPK, 19%,
25%, 39%, respectively (P < .05). No correlation was found between aberrant methylation and immunophenotypic
markers, cytogenetic features, progression-free survival, and overall survival in patients with MM. Conclusions: The
current study supports a relevant role for p15, p16, and DAPK hypermethylation in the genesis of the plasma cell
neoplasm. DAPK hypermethylation also might be an important step in the progression from MGUS to MM.
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Aberrant Gene Methylation in Myelomagenesis
Dowhematologic malignancies and is still incurable, mainly because of its
high biological heterogeneity.2-4
According to several authors, MM is consistently preceded by a
monoclonal gammopathy of uncertain signiﬁcance (MGUS)—an
asymptomatic (no CRAB criteria) premalignant entity that has been
reported to have a transformation rate to MM of approximately 1%
per year.1 Smoldering multiple myeloma (SMM) is an intermediate
asymptomatic malignant plasma cell disorder, with a risk of pro-
gression to symptomatic MM of 10% per year, for the ﬁrst 5
years.1,5-8 Indeed, both MGUS and SMM represent the ideal model
for studying MM precursor disease and to deﬁne and develop early
intervention strategies.
Aberrant CpG island methylation has been associated with
various types of human malignancies, with increasing evidence
suggesting that epigenetic events play a relevant role in carcino-
genesis.6,9-12
The progression from MGUS to MM is the result of complex
multistep genetic aberrations in addition to epigenetic modiﬁca-
tions.8,11,13 The aberrant CpG island methylation of gene promoter
regions of a variety of regulatory genes, associated with gene func-
tion silencing (mainly of tumor suppressor genes), has been reported
in human malignancies.14
It was previously demonstrated that hypermethylation of the cell
cycle inhibitors p15 and p16,14-16 of the apoptosis regulator death-
associated protein kinase (DAPK)17,18 and the tumor suppressor
gene p53 occurs in plasma cell disorders.9,12 However, its role in the
transition from MGUS to MM has not been clariﬁed.
The p15 (INK4B) and p16 (INK4A) genes are members of the
INK4 family of cyclin-dependent kinase inhibitors (CDKIs). The
p15 gene is located 25 kb from the p16 gene at 9p21, and their
proteins share signiﬁcant areas of homologous sequences.19,20 The
p53 gene is a tumor suppressor gene that plays a critical role in cell
cycle regulation, apoptosis, and cell senescence, involved in several
physiologic and pathologic processes.9
DAP kinase, codiﬁed by the DAP kinase (DAPK) gene, localized
in chromosome 9q34.1, is a calcium/calmodulin-dependent and
cytoskeletal-associated serine/threonine kinase with death-inducing
functions. DAPK is a positive mediator of apoptosis induced by
interferon-g, tumor necrosis factor-a, and FAS.21-23 The loss of
expression of DAPK is commonly associated with hypermethylation
of the DAPK gene10 and is frequently found in B-cell lymphoma
and some carcinoma cell lines, which highlights its potential role as
a tumor suppressor.22 Furthermore, its expression was detected in
some MM cell lines and in patient-derived primary cells.21
The characterization of the methylation proﬁle of candidate genes
that have been established to play a role in tumorigenesis may
provide signiﬁcant insight into the molecular pathogenesis of
MGUS and MM, in particular, the role of the aberrant methylation
of the 4 described genes. Moreover, although it has been shown that
methylation patterns may be related to clinical behavior, response to
therapy, and survival, data are scarce regarding MGUS, SMM, and
MM.24,25
The aim of this study was to evaluate the role of aberrant
methylation of promoter regions of tumor suppressor genes in the
clonal evolution from MGUS to MM. Thus, we analyzed in
MGUS, SMM, and symptomatic MM patients, the methylation
status of 4 genes—p15, p16, p53, and DAPK—whose promoterClinical Lymphoma, Myeloma & Leukemia December 2016
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scriptional silencing.4,15 We also aimed to explore possible corre-
lations between the clinical and laboratorial features of MGUS,
SMM, and MM and the methylation pattern of the 4 evaluated
genes at diagnosis. A third objective was to evaluate the impact of
the methylation proﬁle of p15, p16, p53, and DAPK, individually or
combined, on progression-free and overall survivals.
Patients and Methods
Patient Characterization
A total of 94 patients with monoclonal gammopathies (38 patients
with symptomatic MM, 8 patients with SMM, 48 patients with
MGUS) and 8 healthy donors were studied. The diagnosis and staging
ofMMandMGUS followed InternationalMyelomaWorkingGroup
criteria. All studies were performed in bone marrow aspirates of pre-
viously untreated patients, collected for diagnostic purposes. The
study was approved by the Ethics Committee of Faculty of Medicine,
University of Coimbra (FMUC) and samples were collected after
informed consent was obtained in accordance with the Declaration of
Helsinki. The main clinical and laboratory characteristics of the
patient cohort are summarized in Table 1. The cytogenetic and
immunophenotypic characteristics are shown in Table 2.
Overall survival was estimated only in patients with MM after a
bortezomib-based regimen followed by high-dose therapy in
transplant-eligible patients (aged  70 years) or after standard-dose
therapy with thalidomide-based regimens or alkylating agents plus
steroids in transplant-ineligible patients.
Methylation-Speciﬁc Polymerase Chain Reaction
One microgram of genomic DNA, obtained from unsorted
bone marrow cells of patients with MM, SMM, and MGUS at
diagnosis and healthy donors, was extracted using the QIAamp
DNA kit (Qiagen, Chatsworth, Calif) and converted using so-
dium bisulﬁte according to the manufacturer’s protocols (Epi-
TectBisulﬁte Kit, Qiagen). Methylation-speciﬁc polymerase chain
reactions (PCRs) of p15, p16, p53, and DAPK were carried out as
previously described,15,16,26 and we used primer sequences for the
methylated and unmethylated promoters (Supplemental Table 1
in the online version).12,27,28 MSP was performed in a thermal
cycler (Mycycler, Bio-Rad, Hercules, Calif) with the following
conditions: 95C for 5 minutes, 35 cycles of 95C for 45 seconds,
annealing temperature for 30 seconds, 72C for 30 seconds, and a
ﬁnal extension of 10 minutes at 72C (Supplemental Table 1 in
the online version). The MSP mixture contained 50 ng of
bisulﬁte-treated DNA, 0.2 mM 20-deoxynucleoside 50-tri-
phosphates, 2 mM MgCl2, 1 PCR buffer, and 2 U of Hot-
starTaq DNA Polymerase (Qiagen). PCR products were resolved
on 4% agarose gels, stained with ethidium bromide, and visual-
ized under ultraviolet illumination.
Statistical Analysis
The association between methylation status and clinical and
laboratorial characteristics was assessed by Fisher exact test or chi-
square test (for categoric variables) and Student t test (for contin-
uous variables). Survival was calculated from the date of diagnosis to
the date of the patient’s last follow-up or death. Overall survival was
estimated according to the KaplaneMeier method. All statisticalar e Universitário de Coimbra from ClinicalKey.com by Elsevier on December 07, 2018.
 Copyright ©2018. Elsevier Inc. All rights reserved.
Table 1 Baseline Clinical and Laboratorial Features of
Patients
MGUS SMM MM
No. of patients 48 8 38
Gender, n (%)
Male 28 (58%) 4 (50%) 17 (45%)
Female 20 (42%) 4 (50%) 21(55%)
Median age, y (range) 71 (39-86) 73 (58-89) 72 (41-87)
Paraprotein subtype,
n (%)
IgG 32 (67%) 6 (75%) 17 (45%)
IgA 12 (25%) 2 (25%) 16 (42%)
IgM 4 (8%) 0 (0%) 0 (0%)
Light chain only,
n (%)
K 0 (0%) 0 (0%) 4 (10%)
L 0 (0%) 0 (0%) 1 (3%)
ISS, n (%)
1 NA NA 8 (21%)
2 NA NA 7 (18%)
3 NA NA 23 (61%)
Bone marrow plasma
cell, median (range) (%)
5 (1-9) 12 (10-16) 30 (3-95)
Bone disease, n (%) 0 (0%) 0 (0%) 27 (71%)
Hemoglobin, mean
(range) (g/dL)
13.8 (11.8-15) 13.4 (11.6-15.2) 9.9 (8.1-16.1)
Serum calcium mean
(range) (mg/dL)
9.6 (9.3-10) 9.6 (8.8-10.5) 9.5 (7.7-13.8)
Serum albumin mean
(range) (g/dL)
4.4 (3.8-5.1) 4.5 (3.5-4.9) 3.5 (1.9-4.9)
Creatinine mean (range)
(mg/dL)
0.71 (0.52-1.7) 0.8 (0.5-1.5) 0.99 (0.27-19.2)
LDH mean (range) (U/L) 182 (135-247) 172 (156-201) 168 (62-381)
b2-microglobulin mean
(range) (mg/mL)
2.19 (1.31-5.74) 2.4 (1.3-6.2) 6.4 (1.6-11.7)
Abbreviations: Ig ¼ immunoglobulin; ISS ¼ international staging system; LDH ¼ lactate de-
hydrogenase; MGUS ¼ monoclonal gammopathy of uncertain signiﬁcance; MM ¼ multiple
myeloma; NA ¼ not applicable; SMM ¼ smoldering multiple myeloma.
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Dowcalculations were performed using Stata 12 statistical software
(StataCorp LP, College Station, Tex). For all tests, P < .05
(2-sided) was regarded as statistically signiﬁcant.Table 2 Baseline Cytogenetic and Immunophenotypic Features of P
Cytogenetic Abnormalities, n/N (%)
t(14q32) 2/24 (8%)
Deleted 17p13.1 locus 0/24 (0%)
t (4;14) 0/24 (0%)
t (11;14) 1/24 (4%)
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Methylation Analysis in Patients With MM, SMM, and
MGUS
The methylation frequencies of p15, p16, p53, and DAPK genes
in bone marrow aspirates from 94 patients with monoclonal gam-
mopathies (38 patients with MM, 8 patients with SMM, and 48
patients with MGUS) are summarized in Figure 1. The methylation
status of the 4 studied tumor suppressor genes is shown in detail in
Supplemental Figure 1 in the online version.
When we analyzed all studied patients with monoclonal gam-
mopathies (n ¼ 94), 52% presented at least 1 hypermethylated gene
(63% of patients with MM and 39% of patients with MGUS, P <
.05). At least 2 simultaneously aberrantly methylated genes were
found in 29% of patients with MM and 10% of patients with
patients (P < .05) (Figure 1).
Aberrant methylation of 1 and 2 genes was detected in 34% and
23% of MM samples and in 29% and 10% of MGUS samples,
respectively. Five percent of patients with MM and none of the
patients with MGUS exhibited methylation of 3 genes. None of the
studied samples presented methylation of the 4 genes.
The prevalence of methylation of DAPK increased from MGUS
to SMM to MM (16%, 25%, and 38%, respectively, P < .05). This
observation was evident when we analyzed the 3 subgroups sepa-
rately and when we analyzed MGUS plus SMM versus MM (P ¼
.035). There were no statistical differences in the prevalence of
methylation in MGUS, SMM, and MM for the 3 remaining genes
(Figure 1).
None of the 8 normal control bone marrows presented aberrant
methylation of the 4 evaluated genes (Supplemental Figure 1 in the
online version). Examples of MSP are shown in Figure 2. The
positive and negative controls showed the expected MSP results
(Figure 2). When more than 1 gene was methylated, no correlation
was identiﬁed between the methylation of a given gene and the
methylation of any other given gene.Association Between Aberrant Methylation of p15, p16,
p53, DAPK, and Clinical Characteristics and Prognosis
We have also explored the potential correlations between the
methylation pattern of the 4 studied genes and the baseline clini-
copathologic features of patients with MM, including age, gender,
type of paraprotein, International Staging System (ISS), hemoglo-
bin, lactate dehydrogenase, b2-microglobulin, calcium and serumatients
1/8 (12.5%) 14/37 (38%)
0/8 (0%) 1/37 (3%)
0/8 (0%) 5/37 (14%)
0/8 (0%) 4/37 (11%)
4/6 (66%) 16/35 (46%)
1/6 (17%) 27/35 (77%)
6/7 (86%) 29/37 (78%)
4/6 (67%) 21/35 (60%)
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Figure 1 Frequencies of Methylation of p15, p16 p53, and DAPK Genes in Patients With Symptomatic Multiple Myeloma (MM),
Smoldering Multiple Myeloma (SMM), and Monoclonal Gammopathy of Uncertain Signiﬁcance (MGUS). Results Are
Expressed in Percentage (%). *P < .05
Abbreviation: DAPK ¼ death-associated protein kinase.
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Dowcreatinine levels, presence of bone disease, cytogenetic abnormal-
ities, and aberrant expression of immunophenotypic markers
(CD27, CD28, CD56, and CD117).
Patients with p16 gene methylation were more likely to have
stage III disease (ISS) (P ¼ .03) and an increased serum creatinineFigure 2 Examples of the Electrophoresis Analysis of the Methylation
p53, and DAPK Genes in Bone Marrow Samples Collected a
Abbreviations: MC ¼ universal methylated control; Pt ¼ patient; UC ¼ universal unmethylated con
Clinical Lymphoma, Myeloma & Leukemia December 2016
nloaded for Anonymous User (n/a) at CONSORTIUM OF PORTUGAL-Centro Hospital
For personal use only. No other uses without permission.level >2 mg/dL (P ¼ .016). There was a statistically signiﬁcant
association between p15 and p53 gene methylation and elevated
lactate dehydrogenase (P ¼ .04 and P ¼ .028, respectively). Patients
with DAPK gene methylation were more likely to have
immunoglobulin-A subtype (P ¼ .04).-Speciﬁc Polymerase Chain Reaction (PCR) Products of p15, p16,
t Diagnosis of Patients With MM (Pt3), SMM (Pt4), and MGUS (Pt2)
trol.
ar e Universitário de Coimbra from ClinicalKey.com by Elsevier on December 07, 2018.
 Copyright ©2018. Elsevier Inc. All rights reserved.
Figure 3 Survival Curves According to Gene Methylation Proﬁle in Symptomatic Patients With MM. KaplaneMeier Overall Survival
Curves Stratiﬁed by the Absence or Presence of 1 or More Methylated Genes (A) and According to p15 (B), p16 (C), p53 (D),
and DAPK (E) Gene Methylation Proﬁle
Abbreviations: MM ¼ multiple myeloma; NS ¼ not signiﬁcant.
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DowNo correlation was found between the methylation status of any of
the studied genes and the ploidy or cytogenetic aberrations, namely,
t(14q32), t(4;11), t(11;14), and del(17p), in patients withMM, SMM,
and MGUS. Furthermore, no statistically signiﬁcant associations were
observed between the methylation status of the evaluated genes, indi-
vidually or aggregated, with any of the analyzed immunophenotypic
features in the 3 groups of patients with plasma cell dyscrasia.
The median follow-up was 28.5, 25, and 31.7 months in the
MM, SMM, and MGUS groups, respectively. According to ournloaded for Anonymous User (n/a) at CONSORTIUM OF PORTUGAL-Centro Hospital
For personal use only. No other uses without permission.results, the presence of methylated genes did not inﬂuence the
overall survival in the MM group. The overall survival curves in the
MM subgroup are shown in Figure 3.
Discussion
Epigenetic modiﬁcations have been recognized as playing a
relevant role in the critical points of cancer initiation and progres-
sion.29 One of the most common and well-deﬁned epigenetic
modiﬁcations involves methylation of CpG dinucleotides in theClinical Lymphoma, Myeloma & Leukemia December 2016 - 717
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Dowpromoter regions of tumor suppressor genes associated with gene
silencing.30
Although it is known that MM is a highly heterogeneous disease
resulting from the accumulation of several genetic and epigenetic
events,8 published data regarding epigenetic events in monoclonal
gammopathies, namely, the methylation proﬁle of tumor suppressor
genes, are limited and controversial.
In this study, we examined the role of aberrant methylation of
promoter regions of tumor suppressor genes (p15, p16, p53, and
DAPK) and their methylation status in the clonal evolution from
MGUS to MM. In all cases, promoter hypermethylation of these
genes was previously found to be associated with transcriptional
silencing.4,15,31,32 We used methylation-speciﬁc PCR analysis
because it is a sensitive and quick method, better suited to the
analysis of large numbers of samples.27,33,34
MSP has been used to detect methylation in both unsorted bone
marrow mononuclear cells and sorted CD138-positive cells (which
includes the tumor clone).15,18,35 Several authors have studied the
methylation of a number of genes in unsorted mononuclear
cells18,33,36 and sorted CD138-positive cells37 in MM and other B-
cell malignancies, with comparable methylation frequencies of p15
and p16,15 which indicates that the technique can be performed in
mononuclear cells.
Overall, we identiﬁed at least 1 hypermethylated gene in 52% of
patients with monoclonal gammopathy, with patients with MM
presenting a signiﬁcantly higher frequency of hypermethylation
(63%) compared with those with MGUS (39%) and no aberrant
methylation status in controls. These results conﬁrm that aberrant
methylation of tumor suppressor genes is a frequently observed
event in patients with monoclonal gammopathies and involves a
number of genes that control different pathways in the development
and progression of MGUS to a more aggressive symptomatic phase,
in agreement with previous studies.14-17,26
Our study also showed that aberrant methylation of p15, p16,
p53, and DAPK is already present in patients with MGUS (15%,
15%, 2%, and 19%, respectively) and increases in symptomatic
MM (21%, 32%, 5%, and 39%, respectively). However, only
DAPK methylation showed a statistically signiﬁcant increase in
patients with MM compared with patients with MGUS (P < .05).
These observations support the hypothesis that aberrant
methylation of p15, p16 p53, and DAPK constitutes an early event
in the pathogenesis and development of plasma cell disorders,
consistent with the results previously published by Stanganelli
et al16 and Ng et al.18
A wide range of frequencies (5.9%-77%) of DAPK methylation
was reported in MM at diagnosis15,16,18,26 and in other neoplasms
(16%-81%),38-40 with some studies reporting that the loss of DAPK
may confer a selective advantage during the multistep process of
metastasis.30 Thus, the loss of DAPK expression provides a unique
mechanism that links suppression of apoptosis to metastasis41 and
may be involved in the clonal progression from MGUS to MM.
One of the most frequent gene alterations in MM is methylation
of the p15 and p16 genes in the 50 upstream region. P15 and p16
proteins are cell cycle regulators involved in the inhibition of
transition from G1 to S phase.37
Frequencies of p15 or p16 gene methylation up to 32% and
53%, respectively, have been reported in MM cases.14-17,26,37Clinical Lymphoma, Myeloma & Leukemia December 2016
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more frequent in MM than in MGUS,13,17,42 whereas others re-
ported identical frequencies.16,26 Guillerm et al37 described fre-
quencies of methylation of the p15 and p16 genes not signiﬁcantly
different among MGUS and MM samples and also between stage
I/II and stage III, suggesting a lack of association with malignant
transformation from MGUS to MM and a possible contribution to
plasma cells immortalization.
In line with these authors, we showed that p15 and p16 gene
methylation is present at similar rates in MGUS and MM cases,
supporting the concept that an alteration of the regulation of cell
cycle, namely, in the transition of G1 to S phase, is a very early
event in the history of MM.
A reduced number of reports compared the methylation status of
tumor suppressor genes among MGUS, SMM, and MM. As in the
current study, Seidl et al26 considered SMM as an individual sub-
group, but the number of patients included was also low (n ¼ 5),
resulting in nonsigniﬁcant differences when compared with MGUS.
The p53 tumor suppressor gene is the most frequently mutated
gene in human cancer (w50% of human tumors), resulting in a
decreased apoptosis in response to DNA damage.4,43 However, this
is rare in MM, but increases with disease progression8,9,44,45 being
relatively infrequent in MM at diagnosis, occurring in 0% to 3% of
patients, and reaching up to 20% of patients with advanced
disease.8,46
P53 gene methylation was reported in 32% to 55% of the
samples from myeloma cell lines.9 This ﬁnding is in contrast with
our results concerning p53 methylation, which was observed in a
low number of MM and MGUS cases (2% and 5%, respectively).
These discrepancies may be related to the sample type (cell lines vs.
patients’ samples).
Another objective of the current study was to examine possible
correlations between clinical and laboratorial features of MGUS,
SMM, and MM and the methylation pattern of the 4 evaluated
genes at diagnosis. We found that patients with p16 gene methyl-
ation were more likely to have advanced ISS stage and an increased
serum creatinine level. We also observed a signiﬁcant association
between p15 methylation and elevated lactate dehydrogenase, as
well as between DAPK gene methylation and an immunoglobulin-A
subtype. These ﬁndings may suggest that hypermethylation of the
studied genes is associated with a more aggressive disease phenotype.
Looking at cytogenetic abnormalities, we did not ﬁnd any asso-
ciation between the methylation pattern of any of the 4 evaluated
genes and the presence of chromosome 13 deletion, t(4;14),
t(11;14), or 17p deletion by ﬂuorescence in situ hybridization.
These results are in accordance with those of Braggio et al15 and
Walker et al11 in all mentioned cytogenetic subgroups, except for
t(4;14), which was associated with a poor prognosis.
We also searched for associations between immunophenotypic
markers with a demonstrated impact on outcome (CD27, CD28,
CD56, and CD117) and the methylation proﬁle of the studied
genes in patients with MM.
The loss of CD27 in MGUS has been linked to MM progres-
sion,47 and the loss of CD56 expression was associated with
extramedullary spreading, aggressive disease, and inferior
progression-free survival, but not overall survival.48 CD117
expression in clonal plasma cells is associated with favorablear e Universitário de Coimbra from ClinicalKey.com by Elsevier on December 07, 2018.
 Copyright ©2018. Elsevier Inc. All rights reserved.
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Dowbiological features and a lower frequency of adverse cytogenetic
characteristics.49 MM plasma cell expression of CD28 in newly
diagnosed patients is a major prognostic predictor of poor clinical
outcome, allowing MM cells to better survive to treatment and
resulting in their selective outgrowth.50
In a multivariate analysis, we evaluated possible correlations
involving methylation proﬁle of p15, p16, p53, and DAPK and each
speciﬁc immunophenotypic marker (CD27, CD28, CD56, and
CD117), and no statistically signiﬁcant associations were found. To
the best of our knowledge, this is the ﬁrst study to investigate possible
associations between immunophenotypic features and methylation
status of tumor suppressor genes in plasma cell dyscrasia.
A third aim of our investigation was to evaluate the impact of the
methylation proﬁle of p15, p16, p53, and DAPK, individually or
combined, on progression-free and overall survival. We did not ﬁnd
any statistically signiﬁcant difference in progression-free survival and
overall survival in MM cases for any individual studied gene or
combination of genes, controlling for age and treatment approaches.
Our ﬁndings are in agreement with the reports of Guillerm et al,37
who observed that methylation of p15 and p16 was not associated
with shorter survival in patients with MM. In contrast, some studies
noted that DAPK methylation was related to inferior overall survival
and reported that p16 methylation also was associated with a worse
prognosis in patients with MM.17,42
Conclusions
Aberrant methylation of CpG islands in promoter regions of
crucial genes involved in cell cycle regulation, apoptosis, and tumor
suppression is frequent and early events in plasma cell immortali-
zation, leading to the development of monoclonal gammopathies.
However, the relevance of methylation in the clonal evolution from
MGUS to MM and the associations between cytogenetic and
epigenetic events in this malignant transformation remain unclear.
According to our investigation, DAPK methylation may be a marker
of disease progression in monoclonal gammopathies. Another un-
solved question is the prognostic impact of methylation of indi-
vidual and combined genes in MM. Although several authors have
reported a poor prognosis of p16 and DAPK methylation in patients
with MM, this negative impact on outcome was not conﬁrmed in
more recent reports, namely, in the current study. To answer all of
the questions about the role of epigenetic mechanism during
myelomagenesis, a larger study with a longer follow-up and uniform
treatment approaches for patients with MM will be necessary.
Clinical Practice Points
 Multiple myeloma (MM) is associated with genetic, epigenetic,
and bone marrow microenvironment alterations, and currently
remains incurable.
 Increasing evidence supports that epigenetic aberrant modiﬁca-
tions play a relevant role in carcinogenesis and in the progression
from monoclonal gammopathy of uncertain signiﬁcance
(MGUS) to MM.
 Although it was previously demonstrated that hypermethylation
of the cell cycle inhibitors p15 and p16 of the apoptosis regulator
death-associated protein kinase and of the tumor suppressor gene
p53 occurs in plasma cell disorders, its role in myelomagenesis is
not yet clariﬁed.nloaded for Anonymous User (n/a) at CONSORTIUM OF PORTUGAL-Centro Hospital
For personal use only. No other uses without permission. As measured by methylation-speciﬁc polymerase chain reaction
analysis of bone marrow of patients with MGUS and MM and
controls, our study revealed that a large percentage of patients
with MM and MGUS (63% and 39%, respectively) presented at
least 1 hypermethylated gene (P < .05), with no alterations in
normal bone marrow.
 We found no correlation between aberrant methylation and
immunophenotypic markers, cytogenetic features, progression-
free survival, and overall survival in patients with MM. Death-
associated protein kinase methylation also was found to be a
marker of disease progression from MGUS to MM.
 Our study contributed in clarifying the role of the methylation
status of a number of tumor suppressor genes in myelomagenesis
and in the diagnosis, prognosis, and therapeutic approach of
patients with monoclonal gammopathies.Disclosure
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Supplemental Table 1 Methylation-Speciﬁc Polymerase Chain Reaction: Primer Sequences and Reaction Conditions
Gene Forward Primer (50-30) Reverse Primer (30-50) Ta/MgCl2 Reference
P15
M-MSP GCGTTCGTATTTTGCGGTT CGTACAATAACCGAACGACCGA 60C/6.7 mM Herman et al27
U-MSP TGTGATGTGTTTGTATTTTGTGGTT CCATACAATAACCAAACAACCAA 60C/6.7 mM
P16
M-MSP TTATTAGAGGGTGGGGCGGATCGC GACCCCGAACCGCGACCGTAA 65C/6.7 mM Herman et al27
U-MSP TTATTAGAGGGTGGGGTGGATTGT CAACCCCAAACCACAACCATAA 60C/6.7 mM
P53
M-MSP TTCGGTAGGCGGATTATTTG AAATATCCCCGAAACCCAAC 60C/6.7 mM Yeh et al28








Abbreviations: DAPK ¼ DAP kinase; M-MSP ¼ methylation-speciﬁc polymerase chain reaction for the methylated allele; MSP ¼ methylation-speciﬁc polymerase chain reaction; Ta ¼ annealing
temperature; U-MSP ¼ MSP for the unmethylated allele.
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Supplemental Figure 1 Methylation Status of p15, p16, p53, and DAPK Genes in Monoclonal Gammopathy of Uncertain Signiﬁcance
(MGUS) (A), Multiple Myeloma (MM) (B), Smoldering Multiple Myeloma (SMM) (C), and Healthy Controls (D).
White Boxes Represent Unmethylated Samples, and Grey Boxes Represent Methylated Samples.
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